Department of Medicine, Division of Clinical Epidemiology at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Breast Cancer Res Treat. 2011 Feb;126(1):215-20. doi: 10.1007/s10549-010-1224-1. Epub 2010 Oct 26.
Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and clinical evidences suggest that metformin may reduce overall cancer risk and mortality, with specific effects in breast cancer. The extensive clinical experience with metformin, coupled with its known (and modest) toxicity, has allowed the traditional process of drug evaluation to be shortened. We review the rationale for a modified approach to evaluation and outline the key steps that will optimize development of this agent in breast cancer, including discussion of a Phase III adjuvant trial (NCIC MA.32) that has recently been initiated.
二甲双胍是一种廉价的口服药物，常用于治疗 2 型糖尿病，它作为一种潜在的抗癌药物正受到越来越多的关注。临床前、流行病学和临床证据表明，二甲双胍可能降低整体癌症风险和死亡率，对乳腺癌有特殊作用。二甲双胍的广泛临床经验，加上其已知的（适度的）毒性，使得药物评估的传统过程得以缩短。我们回顾了对评估方法进行修改的理由，并概述了优化该药物在乳腺癌中开发的关键步骤，包括最近启动的一项 III 期辅助试验（NCIC MA.32）的讨论。
